{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:43:33Z","timestamp":1790279013930,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"publisher","award":["D1-2023"],"award-info":[{"award-number":["D1-2023"]}],"id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s11102-024-01398-9","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T12:01:55Z","timestamp":1715083315000},"page":"303-309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience"],"prefix":"10.1007","volume":"27","author":[{"given":"Sabrina","family":"Chiloiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amato","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Mattogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liverana","family":"Lauretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Olivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Doglietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"issue":"24","key":"1398_CR1","first-page":"2558","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Acromegaly. New England. J Med 355(24):2558\u20132573","journal-title":"J Med"},{"key":"1398_CR2","doi-asserted-by":"crossref","unstructured":"Frara S, Melin Uygur M, di Filippo L, Doga M, Losa M, Santoro S et al (2022) High Prevalence of Vertebral Fractures Associated With Preoperative GH Levels in Patients With Recent Diagnosis of Acromegaly. J Clin Endocrinol Metab. 107(7):e2843\u201350. https:\/\/academic.oup.com\/jcem\/article\/107\/7\/e2843\/6555665","DOI":"10.1210\/clinem\/dgac183"},{"issue":"6","key":"1398_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3803\/EnM.2023.601","volume":"38","author":"A Giustina","year":"2023","unstructured":"Giustina A (2023) Acromegaly and bone: an update. Endocrinol Metabolism 38(6):655\u2013666","journal-title":"Endocrinol Metabolism"},{"key":"1398_CR4","doi-asserted-by":"publisher","unstructured":"Giustina A (2020) Acromegaly and Vertebral Fractures: Facts and Questions. Trends in Endocrinology and Metabolism. 31(4):274\u20135. https:\/\/doi.org\/10.1016\/j.tem.2020.01.011","DOI":"10.1016\/j.tem.2020.01.011"},{"issue":"9","key":"1398_CR5","doi-asserted-by":"publisher","first-page":"E3285","DOI":"10.1210\/clinem\/dgaa363","volume":"105","author":"G Mazziotti","year":"2020","unstructured":"Mazziotti G, Battista C, Maffezzoni F, Chiloiro S, Ferrante E, Prencipe N et al (2020) Treatment of acromegalic osteopathy in real-life clinical practice: the BAAC (bone active drugs in acromegaly) study. J Clin Endocrinol Metab 105(9):E3285\u2013E3292","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1398_CR6","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11102-018-0873-7","volume":"21","author":"S Chiloiro","year":"2018","unstructured":"Chiloiro S, Mazziotti G, Giampietro A, Bianchi A, Frara S, Mormando M et al (2018) Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. Pituitary 21(3):302\u2013308","journal-title":"Pituitary"},{"issue":"3","key":"1398_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/clinem\/dgz054","volume":"105","author":"S Chiloiro","year":"2020","unstructured":"Chiloiro S, Giampietro A, Frara S, Bima C, Donfrancesco F, Fleseriu CM et al (2020) Effects of Pegvisomant and Pasireotide LAR on Vertebral fractures in Acromegaly resistant to first-generation SRLs. J Clin Endocrinol Metab 105(3):4","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1398_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP et al (2021) Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184(2):217\u2013229","journal-title":"Eur J Endocrinol"},{"key":"1398_CR9","doi-asserted-by":"crossref","unstructured":"Mazziotti G, Canalis E, Giustina A (2010) Drug-induced Osteoporosis: Mechanisms and Clinical Implications. Am J Med. 123(10):877\u201384. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934310004675","DOI":"10.1016\/j.amjmed.2010.02.028"},{"key":"1398_CR10","doi-asserted-by":"publisher","unstructured":"Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW et al (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 16(3):294\u2013302. http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11102-012-0420-x","DOI":"10.1007\/s11102-012-0420-x"},{"key":"1398_CR11","doi-asserted-by":"crossref","unstructured":"Mazziotti G, Frara S, Giustina A (2018) Pituitary Diseases and Bone. Endocr Rev. 39(4):440\u201388. https:\/\/academic.oup.com\/edrv\/article\/39\/4\/440\/4975444","DOI":"10.1210\/er.2018-00005"},{"key":"1398_CR12","doi-asserted-by":"publisher","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (2009) Vertebral fracture assessment using a semiquantitative technique. Journal of Bone and Mineral Research. 8(9):1137\u201348. https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/jbmr.5650080915","DOI":"10.1002\/jbmr.5650080915"},{"issue":"2","key":"1398_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12020-017-1391-5","volume":"59","author":"S Chiloiro","year":"2018","unstructured":"Chiloiro S, Mormando M, Bianchi A, Giampietro A, Milardi D, Bima C et al (2018) Prevalence of morphometric vertebral fractures in difficult patients with acromegaly with different biochemical outcomes after multimodal treatment. Endocrine 59(2):449\u2013453","journal-title":"Endocrine"},{"issue":"6","key":"1398_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.20945\/2359-3997000000185","volume":"63","author":"EO List","year":"2020","unstructured":"List EO, Berryman DE, Jensen EA, Kulkarni P, McKenna S, Kopchick JJ (2020) New insights of growth hormone (GH) actions from tissue-specific GH receptor knockouts in mice. Arch Endocrinol Metab 63(6):557\u2013567","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"1398_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ocr.12554","volume":"25","author":"HJ Park","year":"2022","unstructured":"Park HJ, Ahn SJ, Jang J, Kim S, Park Y, Kim K (2022) Genetic effect of single nucleotide polymorphisms in growth hormone receptor gene on the risk of non-syndromic mandibular prognathism in the Korean population. Orthod Craniofac Res 25(3):437\u2013446","journal-title":"Orthod Craniofac Res"},{"issue":"5","key":"1398_CR16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ajodo.2019.10.020","volume":"158","author":"GA Mara\u00f1\u00f3n-V\u00e1squez","year":"2020","unstructured":"Mara\u00f1\u00f3n-V\u00e1squez GA, Vieira AR, de Carvalho Ramos AG, Dantas B, Romano FL, Palma-Dibb RG et al (2020) GHR and IGF2R genes may contribute to normal variations in craniofacial dimensions: insights from an admixed population. Am J Orthod Dentofac Orthop 158(5):722\u2013730e16","journal-title":"Am J Orthod Dentofac Orthop"},{"issue":"4","key":"1398_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/ejo\/cjx070","volume":"40","author":"SI Tob\u00f3n-Arroyave","year":"2018","unstructured":"Tob\u00f3n-Arroyave SI, Jim\u00e9nez-Arbel\u00e1ez GA, Alvarado-G\u00f3mez VA, Isaza-Guzm\u00e1n DM, Fl\u00f3rez-Moreno GA, P\u00e9rez-Cano MI (2018) Association analysis between rs6184 and rs6180 polymorphisms of growth hormone receptor gene regarding skeletal-facial profile in a Colombian population. Eur J Orthod 40(4):378\u2013386","journal-title":"Eur J Orthod"},{"issue":"5","key":"1398_CR18","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/ijms19051433","volume":"19","author":"S Lin","year":"2018","unstructured":"Lin S, Li C, Li C, Zhang X (2018) Growth hormone receptor mutations related to individual dwarfism. Int J Mol Sci 19(5):1433","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1398_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1530\/EJE-14-0205","volume":"171","author":"M Mormando","year":"2014","unstructured":"Mormando M, Nasto LA, Bianchi A, Mazziotti G, Giampietro A, Pola E et al (2014) GH receptor isoforms and skeletal fragility in acromegaly. Eur J Endocrinol 171(2):237\u2013245","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1398_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40618-019-01096-5","volume":"43","author":"J Pontes","year":"2020","unstructured":"Pontes J, Madeira M, Lima CHA, Ogino LL, de Paula Paranhos Neto F, de Mendon\u00e7a LMC et al (2020) Exon 3-deleted growth hormone receptor isoform is not related to worse bone mineral density or microarchitecture or to increased fracture risk in acromegaly. J Endocrinol Invest 43(2):163\u2013171","journal-title":"J Endocrinol Invest"},{"key":"1398_CR21","doi-asserted-by":"publisher","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B et al (2020) Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 21(4):667\u201378. https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11154-020-09588-z","DOI":"10.1007\/s11154-020-09588-z"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01398-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01398-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01398-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T08:15:22Z","timestamp":1717488922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01398-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01398-9","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"26 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Declaration of competing interest SC, AB, AG, LDM has served as investigator for clinical trials funded by Novartis, Pfizer, Ipsen and Crinetics. SC and AB received grants from Pfizer. SC won the 2022 Arrigo Recordati Research Grant. All the authors declare that there are no conflict of interest that could be perceived as prejudicing the impartiality of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Registry databases were approved by Institutional Review Board (ID:5367) and informed consent was waived for individual patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"(A waiver of subject consent was approved).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"(All authors approve the submission).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}